Meiji Holdings Co., Ltd. (TYO:2269)

Japan flag Japan · Delayed Price · Currency is JPY
3,714.00
+5.00 (0.13%)
May 1, 2026, 3:30 PM JST
Market Cap1.01T +14.0%
Revenue (ttm)1.16T +1.2%
Net Income46.00B -6.8%
EPS169.74 -5.4%
Shares Out271.10M
PE Ratio21.88
Forward PE19.94
Dividend105.00 (2.83%)
Ex-Dividend DateMar 30, 2026
Volume724,100
Average Volume939,655
Open3,686.00
Previous Close3,709.00
Day's Range3,670.00 - 3,730.00
52-Week Range2,907.00 - 4,077.00
Beta0.12
RSI39.99
Earnings DateMay 14, 2026

About Meiji Holdings

Meiji Holdings Co., Ltd., through its subsidiaries, engages in the manufacture and sale of dairy products, confectionery food products and pharmaceuticals in Japan and internationally. The company operates through two segments, Food and Pharmaceuticals. The Food segment provides yogurt, milk, beverages, cheese, butter, margarine, cream, ice cream, prepared food, chocolate, gummy candy, sports nutrition, infant milk, liquid food, beauty products, feed, sugar, and corn sweeteners. The Pharmaceutical segment offers drugs for infectious and central... [Read more]

Founded 1916
Employees 17,231
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 2269
Full Company Profile

Financial Performance

In fiscal year 2025, Meiji Holdings's revenue was 1.15 trillion, an increase of 4.39% compared to the previous year's 1.11 trillion. Earnings were 50.80 billion, an increase of 0.25%.

Financial Statements

News

Meiji Holdings Earnings Call Transcript: Q2 2026

First half operating profit exceeded plan despite a slight sales shortfall, driven by strong pharmaceuticals and effective price increases. Full-year sales guidance was revised down, but profit targets remain, with ongoing structural reforms and new product launches supporting growth.

6 months ago - Transcripts

Meiji Holdings Earnings Call Transcript: Q2 2025

First-half net sales rose 4.2% year-on-year, with operating profit flat and profit attributable to owners down 3.8% due to lower extraordinary gains. Food segment faced cost pressures but expects recovery via price hikes, while pharma segment saw strong first half but faces lower second-half profit from reduced COVID vaccine demand.

1 year ago - Transcripts